ALTH / Allos Therapeutics Inc - SEC-arkivering, Årsberetning, Fuldmagtserklæring

- FORM 15

FORM 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 000-29815 ALLOS THERAPEUTICS, INC. (Exact name of registrant as spe

- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8

Post-Effective Amendment No. 1 to Form S-8 As filed with the Securities and Exchange Commission on September 6, 2012 Registration No. 333-60430 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ALLOS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 54-1655029

- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8

Post-Effective Amendment No. 1 to Form S-8 As filed with the Securities and Exchange Commission on September 6, 2012 Registration No. 333-160680 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ALLOS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 54-165502

- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8

Post-Effective Amendment No. 1 to Form S-8 As filed with the Securities and Exchange Commission on September 6, 2012 Registration No. 333-151882 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ALLOS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 54-165502

ALTH / Allos Therapeutics Inc / Warburg Pincus Private Equity VIII, L.P. - AMENDMENT NO. 5 Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* ALLOS THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 019777101 (CUSIP Number) Scott A. Arenare, Esq. Managing Director and General Counsel Warburg Pincus LLC 450 Lexington Avenue New York, New York 100

- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8

Post-Effective Amendment No. 1 to Form S-8 As filed with the Securities and Exchange Commission on September 6, 2012 Registration No. 333-168436 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ALLOS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 54-165502

AMENDED AND RESTATED BYLAWS OF ALLOS THERAPEUTICS, INC. ARTICLE I

Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ALLOS THERAPEUTICS, INC. ARTICLE I OFFICES Section 1 Registered Office. The registered office of the Corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2 Other Offices. The Corporation may also have offices at such other places both within and without the State of Delaware as the Board of Directors may f

- SCHEDULE 14D-9/A NO. 16

SCHEDULE 14D-9/A NO. 16 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 16) ALLOS THERAPEUTICS, INC. (Name of Subject Company) ALLOS THERAPEUTICS, INC. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class o

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2012 ALLOS THERAPEUTICS, INC.

Spectrum Pharmaceuticals and Allos Therapeutics Announce Expiration of Offering Period and Final Completion of Tender Offer for Shares of Allos Therapeutics

Joint Press Release Exhibit (a)(1)(X) Spectrum Pharmaceuticals and Allos Therapeutics Announce Expiration of Offering Period and Final Completion of Tender Offer for Shares of Allos Therapeutics HENDERSON, Nev.

- AMENDMENT NO. 17 TO SCHEDULE TO

Amendment No. 17 to Schedule TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 17) Allos Therapeutics, Inc. (Name of Subject Company (Issuer)) Sapphire Acquisition Sub, Inc. (Offeror) a wholly owned subsidiary of Spectrum Pharmaceuticals, Inc. (Parent

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION ALLOS THERAPEUTICS, INC. ARTICLE ONE

Amended and Restated Certificate of Incorporation Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ALLOS THERAPEUTICS, INC. ARTICLE ONE The name of the corporation is Allos Therapeutics, Inc. (the “Corporation”). ARTICLE TWO The address of the registered office of the Corporation in the State of Delaware is 2711 Centerville Road, Suite 400, in the City of Wilmington, County of New

Spectrum Pharmaceuticals and Allos Therapeutics Announce That FTC Clears Transaction; Tender Offer for Shares of Allos Common Stock To Expire at 5pm Eastern Time on September 4, 2012

Joint Press Release issued August 28, 2012 Exhibit (a)(1)(w) Spectrum Pharmaceuticals and Allos Therapeutics Announce That FTC Clears Transaction; Tender Offer for Shares of Allos Common Stock To Expire at 5pm Eastern Time on September 4, 2012 • Spectrum intends to accept for payment shares of Allos common stock on September 4, 2012 HENDERSON, Nev.

- SCHEDULE TO (AMENDMENT NO. 16)

Schedule TO (Amendment No. 16) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 16) Allos Therapeutics, Inc. (Name of Subject Company (Issuer)) Sapphire Acquisition Sub, Inc. (Offeror) a wholly owned subsidiary of Spectrum Pharmaceuticals, Inc. (Parent

- SCHEDULE 14D-9/A NO.15

Schedule 14D-9/A No.15 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 15) ALLOS THERAPEUTICS, INC. (Name of Subject Company) ALLOS THERAPEUTICS, INC. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of

- AMENDMENT NO. 15

Amendment No. 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 15) Allos Therapeutics, Inc. (Name of Subject Company (Issuer)) Sapphire Acquisition Sub, Inc. (Offeror) a wholly owned subsidiary of Spectrum Pharmaceuticals, Inc. (Parent of Offeror) CO

CONTINUING EMPLOYEES

Employee FAQs distributed to employees of the Company on August 22, 2012 Exhibit 99A13 August 23, 2012 Employee FAQs The Spectrum and Allos management teams are available to answer questions Allos employees may have regarding Spectrum’s planned acquisition of Allos.

- SCHEDULE 14D-9/A NO.14

Schedule 14D-9/A No.14 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 14) ALLOS THERAPEUTICS, INC. (Name of Subject Company) ALLOS THERAPEUTICS, INC. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of

Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics

EX-99.(A)(12) 2 d399589dex99a12.htm JOINT PRESS RELEASE ISSUED BY THE COMPANY AND SPECTRUM PHARMACEUTICALS Exhibit (a)(12) Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics HENDERSON, Nev. and WESTMINSTER, Colo. – August 17, 2012 – Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (Spectrum) and Allos Therapeutics, I

- AMENDMENT NO.14

Amendment No.14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 14) Allos Therapeutics, Inc. (Name of Subject Company (Issuer)) Sapphire Acquisition Sub, Inc. (Offeror) a wholly owned subsidiary of Spectrum Pharmaceuticals, Inc. (Parent of Offeror) COM

- SCHEDULE 14D-9, AMENDMENT NO. 13

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 13) ALLOS THERAPEUTICS, INC. (Name of Subject Company) ALLOS THERAPEUTICS, INC. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 019777101

License Agreement for 10-Propargyl-10-Deazaaminopterin “PDX” dated December 23, 2002 and amended May 9, 2006 between Allos Therapeutics, Inc. and SRI International, Sloan-Kettering Institute for Cancer Research and Southern Research Institute.

Exhibit 10.1 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES ACT OF 1934, AS AMENDED. LICENSE AGREEMENT THIS LICENSE AGREEMENT, dated as of December 23, 2002, (“Agreement”), is entered into between SRI INTERNATIONAL, a California not-fo

Quarterly Report - 10-Q/A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended June 30, 2012. o Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File

- AMENDMENT NO. 13

Amendment No. 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 13) Allos Therapeutics, Inc. (Name of Subject Company (Issuer)) Sapphire Acquisition Sub, Inc. (Offeror) a wholly owned subsidiary of Spectrum Pharmaceuticals, Inc. (Parent of Offeror) CO

- SCHEDULE 14D-9/A

SCHEDULE 14D-9/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 12) ALLOS THERAPEUTICS, INC. (Name of Subject Company) ALLOS THERAPEUTICS, INC. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Secur

Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics

JOINT PRESS RELEASE BY THE COMPANY AND SPECTRUM PHARMACEUTICALS Exhibit 99a.11 Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics HENDERSON, Nev. and WESTMINSTER, Colo. – August 3, 2012 – Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (Spectrum) and Allos Therapeutics, Inc. (NasdaqGS: ALTH) (Allos) today announced

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended June 30, 2012. o Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 000-29815 Al

- AMENDMENT NO. 12

Amendment No. 12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 12) Allos Therapeutics, Inc. (Name of Subject Company (Issuer)) Sapphire Acquisition Sub, Inc. (Offeror) a wholly owned subsidiary of Spectrum Pharmaceuticals, Inc. (Parent of Offeror) CO

Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics

JOINT PRESS RELEASE BY THE COMPANY AND SPECTRUM PHARMACEUTICALS Exhibit A10 Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics HENDERSON, Nev.

- SCHEDULE 14D-9/A

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 11) ALLOS THERAPEUTICS, INC. (Name of Subject Company) ALLOS THERAPEUTICS, INC. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 019777101

- SCHEDULE TO-T/A

SCHEDULE TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 11) Allos Therapeutics, Inc. (Name of Subject Company (Issuer)) Sapphire Acquisition Sub, Inc. (Offeror) a wholly owned subsidiary of Spectrum Pharmaceuticals, Inc. (Parent of Offeror) COM

Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics

Joint Press Release Exhibit (a)(9) Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics HENDERSON, Nev.

- SCHEDULE 14D9/A

Schedule 14D9/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 10) ALLOS THERAPEUTICS, INC. (Name of Subject Company) ALLOS THERAPEUTICS, INC. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securi

- SC TO-T/A

SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 10) Allos Therapeutics, Inc. (Name of Subject Company (Issuer)) Sapphire Acquisition Sub, Inc. (Offeror) a wholly owned subsidiary of Spectrum Pharmaceuticals, Inc. (Parent of Offeror) COMMON ST

- SCHEDULE 14D-9

SCHEDULE 14D-9 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 9) ALLOS THERAPEUTICS, INC. (Name of Subject Company) ALLOS THERAPEUTICS, INC. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securiti

Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2012 (June 21, 2012) ALLOS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-29815 54-1655029 (State or other jurisdiction (Commission (I

- AMENDMENT NO. 9 TO SCHEDULE TO-T/A

Amendment No. 9 to Schedule TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 9) Allos Therapeutics, Inc. (Name of Subject Company (Issuer)) Sapphire Acquisition Sub, Inc. (Offeror) a wholly owned subsidiary of Spectrum Pharmaceuticals, Inc. (Pare

Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics

Exhibit (a)(8) Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics HENDERSON, Nev.

- SCHEDULE 14D-9, AMENDMENT NO. 8

Schedule 14D-9, Amendment No. 8 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 8) ALLOS THERAPEUTICS, INC. (Name of Subject Company) ALLOS THERAPEUTICS, INC. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of

- SCHEDULE 14D-9, AMENDMENT NO. 7

Schedule 14D-9, Amendment No. 7 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 7) ALLOS THERAPEUTICS, INC. (Name of Subject Company) ALLOS THERAPEUTICS, INC. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of

- SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 8) Allos Therapeutics, Inc. (Name of Subject Company (Issuer)) Sapphire Acquisition Sub, Inc. (Offeror) a wholly owned subsidiary of Spectrum Pharmaceuticals, Inc. (Parent of Offeror) COMMON STOCK, $0.001

Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics

Exhibit (a)(7) Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics HENDERSON, Nev.

Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics

EX-99.(A)(6) 2 d358486dex99a6.htm JOINT PRESS RELEASE Exhibit (a)(6) Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics HENDERSON, Nev. and WESTMINSTER, Colo. – May 24, 2012 – Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (Spectrum) and Allos Therapeutics, Inc. (NasdaqGS: ALTH) (Allos) today announced that Spectru

- AMENDMENT NO. 6 TO SCHEDULE 14D-9

Amendment No. 6 to Schedule 14D-9 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 6) ALLOS THERAPEUTICS, INC. (Name of Subject Company) ALLOS THERAPEUTICS, INC. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title o

- AMENDMENT NO. 7 TO SCHEDULE TO-T

Amendment No. 7 to Schedule TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 7) Allos Therapeutics, Inc. (Name of Subject Company (Issuer)) Sapphire Acquisition Sub, Inc. (Offeror) a wholly owned subsidiary of Spectrum Pharmaceuticals, Inc. (Parent

Spectrum Pharmaceuticals and Allos Therapeutics Announce Extension of Previously Announced Tender Offer For Shares of Allos Therapeutics Federal Trade Commission Has Requested Additional Information

Exhibit (a)(5) Spectrum Pharmaceuticals and Allos Therapeutics Announce Extension of Previously Announced Tender Offer For Shares of Allos Therapeutics Federal Trade Commission Has Requested Additional Information HENDERSON, Nevada and WESTMINSTER, Colo.

- AMENDMENT NO. 5 TO SC 14D-9

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 5) ALLOS THERAPEUTICS, INC. (Name of Subject Company) ALLOS THERAPEUTICS, INC. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 019777101 (

- AMENDMENT NO. 6 TO SC TO-T

Amendment No. 6 to SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 6) Allos Therapeutics, Inc. (Name of Subject Company (Issuer)) Sapphire Acquisition Sub, Inc. (Offeror) a wholly owned subsidaiary of Spectrum Pharmaceuticals, Inc. (Parent of O

- AMENDMENT NO 4 TO SCHEDULE 14D-9

Amendment No 4 to Schedule 14D-9 SECURITIES AND EXCHANGE COMMISSION Washington, D.

MEMORANDUM OF UNDERSTANDING

Memorandum of Understanding Exhibit (g)(6) MEMORANDUM OF UNDERSTANDING WHEREAS, there are class action lawsuits currently pending in the Delaware Court of Chancery (the “Court”), entitled In re Allos Therapeutics, Inc.

- SCHEDULE TO

Schedule TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5) Allos Therapeutics, Inc. (Name of Subject Company (Issuer)) Sapphire Acquisition Sub, Inc. (Offeror) a wholly owned subsidaiary of Spectrum Pharmaceuticals, Inc. (Parent of Offeror) COMMON

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended March 31, 2012. o Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 000-29815 A

- AMENDMENT NO. 3 TO SC 14D-9

SC 14D9/A 1 d343840dsc14d9a.htm AMENDMENT NO. 3 TO SC 14D-9 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) ALLOS THERAPEUTICS, INC. (Name of Subject Company) ALLOS THERAPEUTICS, INC. (Name of Persons Filing Statement) Common Stock, par value

- AMENDMENT NO. 4 TO SCHEDULE TO-T

Amendment No. 4 to Schedule TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) Allos Therapeutics, Inc. (Name of Subject Company (Issuer)) Sapphire Acquisition Sub, Inc. (Offeror) a wholly owned subsidaiary of Spectrum Pharmaceuticals, Inc. (Paren

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLORADO

Exhibit (g)(5) Exhibit (g)(5) IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLORADO Civil Action No.

CERTIFICATION

EXHIBIT 31.02 CERTIFICATION I, David C. Clark, certify that: 1. I have reviewed this Amendment No. 1 to the annual report on Form 10-K/A of Allos Therapeutics, Inc.; and 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were

Annual Report - 10-K/A

10-K/A 1 a12-11191110ka.htm 10-K/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2011. o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition per

CERTIFICATION

EXHIBIT 31.01 CERTIFICATION I, Paul L. Berns, certify that: 1. I have reviewed this Amendment No. 1 to the annual report on Form 10-K/A of Allos Therapeutics, Inc.; and 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were m

-

SEC Response Letter 300 North LaSalle Street Chicago, Illinois 60654 (312) 862-2000 Facsimile: (312) 862-2200 www.

- AMENDMENT NO. 3 TO SCHEDULE TO-T

Amendment No. 3 to Schedule TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) Allos Therapeutics, Inc. (Name of Subject Company (Issuer)) Sapphire Acquisition Sub, Inc. (Offeror) a wholly owned subsidiary of Spectrum Pharmaceuticals, Inc. (Parent

- AMENDMENT NO. 2 TO SCHEDULE TO-T

SC TO-T/A 1 d339131dsctota.htm AMENDMENT NO. 2 TO SCHEDULE TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) Allos Therapeutics, Inc. (Name of Subject Company (Issuer)) Sapphire Acquisition Sub, Inc. (Offeror) a wholly owned subsidaiary of Spectr

-

300 North LaSalle Street Chicago, Illinois 60654 (312) 862-2000 www.kirkland.com Facsimile: (312) 862-2200 April 24, 2012 By Electronic Transmission Securities and Exchange Commission Office of Mergers and Acquisitions Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Peggy Kim, Esq. Re: Allos Therapeutics Amendment No. 1 to Schedule TO filed on April 16, 2012 Sc

PLEASE NOTE THAT THIS EMAIL WAS DIRECTED TO ALLOS EMPLOYEES AND DOES NOT RELATE TO TENDERS BY OTHER ALLOS STOCKHOLDERS.

EX-99.A.4 Exhibit (a)(4) PLEASE NOTE THAT THIS EMAIL WAS DIRECTED TO ALLOS EMPLOYEES AND DOES NOT RELATE TO TENDERS BY OTHER ALLOS STOCKHOLDERS. ACTION REQUIRED – ELECTION FOR THE TENDER OFFER Dear Allos Employees: Merrill Lynch has mailed the instructions and materials regarding the Tender Offer to your home address. This information requires you to make an election whether to tender your shares

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE ) ) Consolidated IN RE ALLOS THERAPEUTICS, INC. ) C.A. No. 6714-VCN SHAREHOLDERS LITIGATION ) ) CONFIDENTIAL ) FILED UNDER SEAL ) VERIFIED SECOND AMENDED CLASS ACTION COMPLAINT FOR BREACH OF FIDUCIARY

EX-99.G.4 Exhibit (g)(4) IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE ) ) Consolidated IN RE ALLOS THERAPEUTICS, INC. ) C.A. No. 6714-VCN SHAREHOLDERS LITIGATION ) ) CONFIDENTIAL ) FILED UNDER SEAL ) VERIFIED SECOND AMENDED CLASS ACTION COMPLAINT FOR BREACH OF FIDUCIARY DUTY Plaintiffs Hoyan Lam, Offer Ellbogen and Stanley Bondarowicz (“Plaintiffs”), by their attorneys, allege upon informatio

- AMENDMENT TO SCHEDULE 14D-9

AMENDMENT TO SCHEDULE 14D-9 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) ALLOS THERAPEUTICS, INC. (Name of Subject Company) ALLOS THERAPEUTICS, INC. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Clas

VERFIED AMENDED CLASS ACTION COMPLAINT

EX-99.G.3 Exhibit (g)(3) IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE ERNEST KEUCHER, Individually and On ) Behalf of All Others Similarly Situated, ) ) Plaintiff, ) ) v. ) C.A. No. 7419-VCN ) PAUL L. BERNS, CECILIA GONZALO, ) STEPHEN J. HOFFMAN, JEFFREY R. ) LATTS, JONATHAN S. LEFF, DAVID M. ) STOUT, JOSEPH L. TURNER, ALLOS ) THERAPEUTICS, INC., SPECTRUM ) PHARMACEUTICALS, INC. and ) SAPPHIR

- SCHEDULE 14D-9/A

SCHEDULE 14D-9/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) ALLOS THERAPEUTICS, INC. (Name of Subject Company) ALLOS THERAPEUTICS, INC. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securi

Financial Statements and Exhibits, Other Events - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2012 (April 20, 2012) ALLOS THERAPEUTICS, INC.

Allos Therapeutics Announces Outcome of Request for Re-examination of CHMP Opinion for FOLOTYN® in Europe

Press Release Exhibit 99.1 Contact: Monique Greer 720-540-5268 [email protected] Allos Therapeutics Announces Outcome of Request for Re-examination of CHMP Opinion for FOLOTYN® in Europe WESTMINSTER, Colo., April 20, 2012 – Allos Therapeutics, Inc. (NASDAQ: ALTH) announced today that following its request for re-examination, the European Medicines Agency’s Committee For Medicinal Products for Human

- SCHEDULE TO-T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Allos Therapeutics, Inc. (Name of Subject Company (Issuer)) Sapphire Acquisition Sub, Inc. (Offeror) a wholly owned subsidiary of Spectrum Pharmaceuticals, Inc. (Parent of Offeror) COMMON STOCK, $0.001 PAR VALUE PER SHA

157 Technology Dr • Irvine, California 92618 • Tel: 949-788-6700 • Fax: 949-788-6706 11500 South Eastern Ave. • Suite 240 • Henderson, NV, 89052 • Tel: 949-788-6700 • Fax: 949-788-6706 www.sppirx.com • NASDAQ: SPPI

EX-99.E.5 3 d332565dex99e5.htm EX-99.E.5 Exhibit (e)(5) STRICTLY PRIVATE AND CONFIDENTIAL March 19, 2012 Allos Therapeutics, Inc. 11080 CirclePoint Road, Ste. 200 Westminster, Colorado 80020 Attention: Paul L. Berns Ladies and Gentlemen: Spectrum Pharmaceuticals, Inc. (the “Buyer”) is pleased to be given the opportunity to proceed with discussions with respect to an acquisition (the “Potential Tra

Offer to Purchase for Cash All Outstanding Shares of Common Stock ALLOS THERAPEUTICS, INC. $1.82 Net Per Share, Plus One Non-Transferable Contingent Value Right Per Share to Receive $0.11 Per Share Upon the Achievement of Specified Milestones SAPPHIR

Table of Contents Exhibit (a)(1)(A) Offer to Purchase for Cash All Outstanding Shares of Common Stock of ALLOS THERAPEUTICS, INC.

LETTER OF TRANSMITTAL To Tender Shares of Common Stock ALLOS THERAPEUTICS, INC., a Delaware corporation $1.82 NET PER SHARE, PLUS ONE NON-TRANSFERABLE CONTINGENT VALUE RIGHT PER SHARE TO RECEIVE $0.11 PER SHARE UPON THE ACHIEVEMENT OF SPECIFIED MILES

EX-99.A.1.B Exhibit (a)(1)(B) LETTER OF TRANSMITTAL To Tender Shares of Common Stock of ALLOS THERAPEUTICS, INC., a Delaware corporation at $1.82 NET PER SHARE, PLUS ONE NON-TRANSFERABLE CONTINGENT VALUE RIGHT PER SHARE TO RECEIVE $0.11 PER SHARE UPON THE ACHIEVEMENT OF SPECIFIED MILESTONES Pursuant to the Offer to Purchase dated April 13, 2012 By SAPPHIRE ACQUISITION SUB, INC., a Delaware corpora

- SC 14D9

SC 14D9 Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ALLOS THERAPEUTICS, INC. (Name of Subject Company) ALLOS THERAPEUTICS, INC. (Name of Person Filing Statement) Common Stock, par value $.001 per share (Title of Class of Securities) 01977

Bank of America, N.A. Merrill Lynch, Pierce, Fenner & Smith Incorporated 214 North Tryon Street Charlotte, North Carolina 28255

Exhibit (d)(4) Bank of America, N.A. Merrill Lynch, Pierce, Fenner & Smith Incorporated 214 North Tryon Street Charlotte, North Carolina 28255 April 4, 2012 Spectrum Pharmaceuticals, Inc. 11500 South Eastern Avenue, Suite 240 Henderson, Nevada 89052 Attention: Rajesh C. Shrotriya, MD, Chairman and Chief Executive Officer Re: $75,000,000 Senior Credit Facility – Commitment Letter Ladies and Gentlem

NOTICE OF GUARANTEED DELIVERY For Tender of Shares of Common Stock ALLOS THERAPEUTICS, INC., a Delaware corporation $1.82 NET PER SHARE, PLUS ONE NON-TRANSFERABLE CONTINGENT VALUE RIGHT PER SHARE TO RECEIVE $0.11 PER SHARE UPON THE ACHIEVEMENT OF SPE

EX-99.A.1.C 4 d332524dex99a1c.htm EX-99.A.1.C Exhibit (a)(1)(C) NOTICE OF GUARANTEED DELIVERY For Tender of Shares of Common Stock of ALLOS THERAPEUTICS, INC., a Delaware corporation at $1.82 NET PER SHARE, PLUS ONE NON-TRANSFERABLE CONTINGENT VALUE RIGHT PER SHARE TO RECEIVE $0.11 PER SHARE UPON THE ACHIEVEMENT OF SPECIFIED MILESTONES Pursuant to the Offer to Purchase dated April 13, 2012 by SAPP

Offer To Purchase For Cash All Outstanding Shares of Common Stock ALLOS THERAPEUTICS, INC., a Delaware corporation $1.82 NET PER SHARE, PLUS ONE NON-TRANSFERABLE CONTINGENT VALUE RIGHT PER SHARE TO RECEIVE $0.11 PER SHARE UPON THE ACHIEVEMENT OF SPEC

Exhibit (a)(1)(E) Offer To Purchase For Cash All Outstanding Shares of Common Stock of ALLOS THERAPEUTICS, INC.

This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is made solely by the Offer to Purchase, dated April 13, 2012, and the related Letter of Transmittal and

Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below).

- AMENDMENT NO. 1 TO SCHEDULE TO

Amendment No. 1 to Schedule TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) Allos Therapeutics, Inc. (Name of Subject Company (Issuer)) Sapphire Acquisition Sub, Inc. (Offeror) a wholly owned subsidiary of Spectrum Pharmaceuticals, Inc. (Parent o

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE ERNEST KEUCHER, Individually and On ) Behalf of All Others Similarly Situated, ) ) Plaintiff, ) ) v. ) Civil Action No. ) PAUL L. BERNS, CECILIA GONZALO, ) STEPHEN J. HOFFMAN, JEFFREY R. ) LATTS, JONA

EX-99.G.2 6 d332565dex99g2.htm EX-99.G.2 Exhibit (g)(2) IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE ERNEST KEUCHER, Individually and On ) Behalf of All Others Similarly Situated, ) ) Plaintiff, ) ) v. ) Civil Action No. ) PAUL L. BERNS, CECILIA GONZALO, ) STEPHEN J. HOFFMAN, JEFFREY R. ) LATTS, JONATHAN S. LEFF, DAVID M. ) STOUT, JOSEPH L. TURNER, ALLOS ) THERAPEUTICS, INC., SPECTRUM ) PHARM

157 Technology Dr • Irvine, California 92618 • Tel: 949-788-6700 • Fax: 949-788-6706 11500 South Eastern Ave. • Suite 240 • Henderson, NV, 89052 • Tel: 949-788-6700 • Fax: 949-788-6706 www.sppirx.com • NASDAQ: SPPI

EX-99.E.6 Exhibit (e)(6) STRICTLY PRIVATE AND CONFIDENTIAL March 30, 2012 Allos Therapeutics, Inc. 11080 CirclePoint Road, Ste. 200 Westminster, Colorado 80020 Attention: Paul L. Berns Ladies and Gentlemen: Spectrum Pharmaceuticals, Inc. (the “Buyer”) is pleased to be given the opportunity to proceed with discussions with respect to an acquisition (the “Potential Transaction”) of Allos Therapeutic

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLORADO

Exhibit (g)(1) IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLORADO Civil Action No.

SCHEDULE 13D JOINT FILING AGREEMENT

EX-99.1 2 d335770dex991.htm JOINT FILING AGREEMENT CUSIP No. 019777101 Page 14 of 21 SCHEDULE 13D JOINT FILING AGREEMENT The undersigned hereby agree as follows: Each of them is individually eligible to use the Schedule 13D to which this Exhibit is attached, and such Schedule 13D is filed on behalf of each of them; and Each of them is responsible for the timely filing of such Schedule 13D and any

SPECTRUM PHARMACEUTICALS COMMENCES TENDER OFFER FOR ALL OUTSTANDING SHARES OF ALLOS THERAPEUTICS

Exhibit (a)(1)(J) SPECTRUM PHARMACEUTICALS COMMENCES TENDER OFFER FOR ALL OUTSTANDING SHARES OF ALLOS THERAPEUTICS HENDERSON, Nevada, Monday, April 16, 2012 – Spectrum Pharmaceuticals (NASDAQ: SPPI) today announced that it commenced on Friday, April 13, 2012 a cash tender offer to purchase all of the outstanding shares of common stock of Allos Therapeutics, Inc.

CONFIDENTIALITY AGREEMENT

EX-99.E.4 2 d332565dex99e4.htm EX-99.E.4 Exhibit (e)(4) CONFIDENTIALITY AGREEMENT THIS CONFIDENTIALITY AGREEMENT (“Agreement”) is being entered into as of September 23, 2011, between Allos Therapeutics, Inc. (“Allos”) and Spectrum Pharmaceuticals, Inc. (“Spectrum”). In order to facilitate the consideration and negotiation of a possible negotiated transaction involving Allos and Spectrum (referred

Offer To Purchase For Cash All Outstanding Shares of Common Stock ALLOS THERAPEUTICS, INC., a Delaware corporation $1.82 NET PER SHARE, PLUS ONE NON-TRANSFERABLE CONTINGENT VALUE RIGHT PER SHARE TO RECEIVE $0.11 PER SHARE UPON THE ACHIEVEMENT OF SPEC

EX-99.A.1.D 5 d332524dex99a1d.htm EX-99.A.1.D Exhibit (a)(1)(D) Offer To Purchase For Cash All Outstanding Shares of Common Stock of ALLOS THERAPEUTICS, INC., a Delaware corporation at $1.82 NET PER SHARE, PLUS ONE NON-TRANSFERABLE CONTINGENT VALUE RIGHT PER SHARE TO RECEIVE $0.11 PER SHARE UPON THE ACHIEVEMENT OF SPECIFIED MILESTONES Pursuant to the Offer to Purchase dated April 13, 2012 by SAPPH

ALTH / Allos Therapeutics Inc / SPECTRUM PHARMACEUTICALS INC - SCHEDULE 13D Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Allos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.011 per share (Title of Class of Securities) 019777101 (CUSIP Number) Rajesh C. Shrotriya, M.D. Spectrum Pharmaceuticals, Inc. 11500 South Eastern Ave., Suite 240 Henderson, Nevada 89052 (702) 835-6300 (Name, Address a

ALTH / Allos Therapeutics Inc / Warburg Pincus Private Equity VIII, L.P. - SCHEDULE 13D, AMENDMENT 4 Activist Investment

SC 13D/A 1 w7634425a.htm SCHEDULE 13D, AMENDMENT 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* ALLOS THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 019777101 (CUSIP Number) Scott A. Arenare, Esq. Managing Director and General Counsel Warburg Pin

TENDER AND VOTING AGREEMENT

Exhibit 99.1 TENDER AND VOTING AGREEMENT This Tender and Voting Agreement, dated as of April 4, 2012 (this “Agreement”), is by and among SPECTRUM PHARMACEUTICALS, INC., a Delaware corporation (“Parent”), SAPPHIRE ACQUISITION SUB, INC., a Delaware corporation (“Merger Sub”), and the stockholder of ALLOS THERAPEUTICS, INC., a Delaware corporation (the “Company”), set forth on the signature page here

- SC14D9C

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ALLOS THERAPEUTICS, INC. (Name of Subject Company) ALLOS THERAPEUTICS, INC. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 019777101 (CUSIP Number of Cl

TENDER AND VOTING AGREEMENT

Exhibit 2.3 TENDER AND VOTING AGREEMENT This Tender and Voting Agreement, dated as of April 4, 2012 (this “Agreement”), is by and among SPECTRUM PHARMACEUTICALS, INC., a Delaware corporation (“Parent”), SAPPHIRE ACQUISITION SUB, INC., a Delaware corporation (“Merger Sub”), and the stockholder of ALLOS THERAPEUTICS, INC., a Delaware corporation (the “Company”), set forth on the signature page heret

CONTINGENT VALUE RIGHTS AGREEMENT

Exhibit 2.2 EXHIBIT D CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [ ], 2012 (this “Agreement”), is entered into by and among SPECTRUM PHARMACEUTICALS, INC., a Delaware corporation (“Parent”), ALLOS THERAPEUTICS, INC., a Delaware corporation (the “Company”) and [ ], as Rights Agent (the “Rights Agent”). RECITALS A. Parent, Sapphire Acquisition Sub, Inc., a

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2012 (April 4, 2012) ALLOS THERAPEUTICS, INC.

AGREEMENT AND PLAN OF MERGER SPECTRUM PHARMACEUTICALS, INC., a Delaware corporation; SAPPHIRE ACQUISITION SUB, INC., a Delaware corporation; and ALLOS THERAPEUTICS, INC., a Delaware corporation Dated as of April 4, 2012

Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER among: SPECTRUM PHARMACEUTICALS, INC., a Delaware corporation; SAPPHIRE ACQUISITION SUB, INC., a Delaware corporation; and ALLOS THERAPEUTICS, INC., a Delaware corporation Dated as of April 4, 2012 Table of Contents Page Section 1. THE OFFER 2 The Offer 2 Company Action 5 Adjustment to Merger Consideration 7 Top-Up 7 Company Board Represen

AMENDMENT TO RIGHTS AGREEMENT

Exhibit 2.4 AMENDMENT TO RIGHTS AGREEMENT THIS AMENDMENT (the “Amendment”), dated as of the 4th day of April, 2012, to the Rights Agreement (the “Rights Agreement”), dated May 6, 2003, as amended by Amendment No. 1 dated as of March 4, 2005, Amendment No. 2 dated as of January 29, 2007, Amendment No. 3 dated as of July 17, 2009 and Amendment No. 4 dated as of July 19, 2011 (the “Terminated Amendme

CONTINGENT VALUE RIGHTS AGREEMENT

EX-2.2 Exhibit 2.2 CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [ ], 2012 (this “Agreement”), is entered into by and among SPECTRUM PHARMACEUTICALS, INC., a Delaware corporation (“Parent”), ALLOS THERAPEUTICS, INC., a Delaware corporation (the “Company”) and [ ], as Rights Agent (the “Rights Agent”). RECITALS A. Parent, Sapphire Acquisition Sub, Inc., a Del

www.CallStreet.com • 1-877-FACTSET • Copyright © 2001-2012 CallStreet 1 Spectrum Pharmaceuticals, Inc. SPPI Acquisition of Allos Therapeutics, Inc by Spectrum Pharmaceuticals, Inc. Call Apr. 5, 2012 Company p Ticker p Event Type p Date p

EX-99.2 Exhibit 99.2 Spectrum Pharmaceuticals, Inc. SPPI Acquisition of Allos Therapeutics, Inc by Spectrum Pharmaceuticals, Inc. Call Apr. 5, 2012 Company p Ticker p Event Type p Date p PARTICIPANTS Corporate Participants Shiv Kapoor – Vice President, Strategic Planning & Investor Relations, Spectrum Pharmaceuticals, Inc. Rajesh C. Shrotriya – Chairman, Chief Executive Officer & President Brett L

SPECTRUM PHARMACEUTICALS TO ACQUIRE ALLOS THERAPEUTICS: ACQUISITION EXPECTED TO BE ACCRETIVE ON A CASH BASIS IN Q4 OF 2012

EX-99.1 5 d330014dex991.htm EX-99.1 Exhibit 99.1 COMPANY CONTACT Spectrum Pharmaceuticals Shiv Kapoor Vice President, Strategic Planning & Investor Relations 702-835-6300 Allos Therapeutics Monique Greer Vice President, Corporate Communications & Investor Relations 720-540-5268 SPECTRUM PHARMACEUTICALS TO ACQUIRE ALLOS THERAPEUTICS: ACQUISITION EXPECTED TO BE ACCRETIVE ON A CASH BASIS IN Q4 OF 201

- SC14D9C

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ALLOS THERAPEUTICS, INC. (Name of Subject Company) ALLOS THERAPEUTICS, INC. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 019777101 (CUSIP Number of Cl

- SC14D9C

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ALLOS THERAPEUTICS, INC. (Name of Subject Company) ALLOS THERAPEUTICS, INC. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 019777101 (CUSIP Number of Cl

TENDER AND VOTING AGREEMENT

EX-2.3 Exhibit 2.3 TENDER AND VOTING AGREEMENT This Tender and Voting Agreement, dated as of April 4, 2012 (this “Agreement”), is by and among SPECTRUM PHARMACEUTICALS, INC., a Delaware corporation (“Parent”), SAPPHIRE ACQUISITION SUB, INC., a Delaware corporation (“Merger Sub”), and the stockholder of ALLOS THERAPEUTICS, INC., a Delaware corporation (the “Company”), set forth on the signature pag

- FORM 8-K

FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2012 SPECTRUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporatio

AGREEMENT AND PLAN OF MERGER SPECTRUM PHARMACEUTICALS, INC., a Delaware corporation; SAPPHIRE ACQUISITION SUB, INC., a Delaware corporation; and ALLOS THERAPEUTICS, INC., a Delaware corporation Dated as of April 4, 2012 Table of Contents Page Section

EX-2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER among: SPECTRUM PHARMACEUTICALS, INC., a Delaware corporation; SAPPHIRE ACQUISITION SUB, INC., a Delaware corporation; and ALLOS THERAPEUTICS, INC., a Delaware corporation Dated as of April 4, 2012 Table of Contents Page Section 1. THE OFFER 2 1.1 The Offer 2 1.2 Company Action 5 1.3 Adjustment to Merger Consideration 7 1.4 Top-Up 7

ALLOS THERAPEUTICS, INC. SECOND AMENDMENT TO EMPLOYMENT AGREEMENT BRUCE K. BENNETT, JR.

QuickLinks - Click here to rapidly navigate through this document Exhibit 10.20.2 ALLOS THERAPEUTICS, INC. SECOND AMENDMENT TO EMPLOYMENT AGREEMENT BRUCE K. BENNETT, JR. This SECOND AMENDMENT TO EMPLOYMENT AGREEMENT (this "Second Amendment") is entered into effective as of September 6, 2011, by and between ALLOS THERAPEUTICS, INC. (the "Company") and BRUCE K. BENNETT, JR. ("Executive") (collective

AMENDED AND RESTATED SECOND AMENDMENT TO LEASE

QuickLinks - Click here to rapidly navigate through this document Exhibit 10.5.1 AMENDED AND RESTATED SECOND AMENDMENT TO LEASE THIS AMENDED AND RESTATED SECOND AMENDMENT TO LEASE ("Amendment") is made and entered into as of the 9th day of December, 2002, by and between CATELLUS DEVELOPMENT CORPORATION, a Delaware corporation ("Landlord"), and ALLOS THERAPEUTICS, INC., a Delaware corporation ("Ten

ALLOS THERAPEUTICS, INC. SECOND AMENDMENT TO EMPLOYMENT AGREEMENT CHARLES MORRIS

QuickLinks - Click here to rapidly navigate through this document Exhibit 10.19.2 ALLOS THERAPEUTICS, INC. SECOND AMENDMENT TO EMPLOYMENT AGREEMENT CHARLES MORRIS This SECOND AMENDMENT TO EMPLOYMENT AGREEMENT (this "Second Amendment") is entered into effective as of September 7, 2011, by and between ALLOS THERAPEUTICS, INC. (the "Company") and CHARLES MORRIS ("Executive") (collectively, the "Parti

ALLOS THERAPEUTICS, INC. SECOND AMENDMENT TO EMPLOYMENT AGREEMENT DAVID CLARK

QuickLinks - Click here to rapidly navigate through this document Exhibit 10.18.2 ALLOS THERAPEUTICS, INC. SECOND AMENDMENT TO EMPLOYMENT AGREEMENT DAVID CLARK This SECOND AMENDMENT TO EMPLOYMENT AGREEMENT (this "Second Amendment") is entered into effective as of September 7, 2011, by and between ALLOS THERAPEUTICS, INC. (the "Company") and DAVID CLARK ("Executive") (collectively, the "Parties").

THIRD AMENDMENT TO LEASE

QuickLinks - Click here to rapidly navigate through this document Exhibit 10.5.2 THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE ("Amendment") is made and entered into as of the 28th day of November 2003, by and between CATELLUS DEVELOPMENT CORPORATION, a Delaware corporation ("Landlord"), and ALLOS THERAPEUTICS, INC., a Delaware corporation ("Tenant"). R E C I T A L S : A. Landlord and Ten

Quarterly Report - 10-Q/A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended September 30, 2011. o Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission F

Consent of Independent Registered Public Accounting Firm

QuickLinks - Click here to rapidly navigate through this document Exhibit 23.01 Consent of Independent Registered Public Accounting Firm We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-60430, 333-151882, 333-160680 and 333-168436) and in the Registration Statement on Form S-3 (No. 333-160679) of our reports dated March 23, 2012, with respect

LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT by and between ALLOS THERAPEUTICS, INC., a Delaware corporation MUNDIPHARMA INTERNATIONAL CORPORATION LIMITED a Bermuda corporation

QuickLinks - Click here to rapidly navigate through this document EXHIBIT 10.25 [ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT by and between ALLOS THERAPEUTICS, INC., a Delawar

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

QuickLinks - Click here to rapidly navigate through this document Exhibit 23.02 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-60430, 333-151882, 333-160680 and 333-168436) and in the Registration Statement on Form S-3 (No 333-160679) of Allos Therapeutics, Inc. of our report dated Ma

SUMMARY OF COMPENSATION ARRANGEMENTS WITH NON-EMPLOYEE DIRECTORS

QuickLinks - Click here to rapidly navigate through this document Exhibit 10.9 SUMMARY OF COMPENSATION ARRANGEMENTS WITH NON-EMPLOYEE DIRECTORS The following description of the compensation arrangements between Allos Therapeutics, Inc. (the "Company") and each of its non-employee directors is provided pursuant to Item 601(b)(10)(iii) of Regulation S-K, which requires a written description of any c

FIFTH AMENDMENT TO OFFICE LEASE AGREEMENT

QuickLinks - Click here to rapidly navigate through this document Exhibit 10.5.3 FIFTH AMENDMENT TO OFFICE LEASE AGREEMENT THIS FIFTH AMENDMENT TO OFFICE LEASE AGREEMENT (this "Amendment"), dated as of June 16, 2008, (the "Effective Date") is entered into by and between CIRCLE POINT PROPERTIES, LLC, a Delaware limited liability company (the "Landlord") and ALLOS THERAPEUTICS, INC., a Delaware corp

ALLOS THERAPEUTICS, INC. SECOND AMENDMENT TO SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT MARC H. GRABOYES

QuickLinks - Click here to rapidly navigate through this document Exhibit 10.16.2 ALLOS THERAPEUTICS, INC. SECOND AMENDMENT TO SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT MARC H. GRABOYES This SECOND AMENDMENT TO SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this "Second Amendment") is entered into effective as of September 7, 2011, by and between ALLOS THERAPEUTICS, INC. (the "Company")

Quarterly Report - 10-Q/A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended June 30, 2011. o Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File N

/s/ PAUL L. BERNS Paul L. Berns President and Chief Executive Officer (Principal Executive Officer) /s/ DAVID C. CLARK David C. Clark Vice President, Finance and Treasurer (Principal Financial and Accounting Officer)

QuickLinks - Click here to rapidly navigate through this document EXHIBIT 32.01 CERTIFICATION Pursuant to the requirements set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. § 1350), Paul L. Berns, the President and Chief Executive Officer of Allos Therapeutics, Inc., a

OFFICE LEASE BY AND BETWEEN CATELLUS DEVELOPMENT CORPORATION, a Delaware corporation, as Landlord and ALLOS THERAPEUTICS, INC., a Delaware corporation, as Tenant. CirclePoint Corporate Center Westminster, Colorado

QuickLinks - Click here to rapidly navigate through this document Exhibit 10.5 OFFICE LEASE BY AND BETWEEN CATELLUS DEVELOPMENT CORPORATION, a Delaware corporation, as Landlord and ALLOS THERAPEUTICS, INC., a Delaware corporation, as Tenant. CirclePoint Corporate Center Westminster, Colorado CA CDC# OFFICE LEASE BASIC LEASE INFORMATION Effective Date: April , 2001 Landlord: CATELLUS DEVELOPMENT CO

ALLOS THERAPEUTICS, INC. SECOND AMENDMENT TO EMPLOYMENT AGREEMENT MICHAEL E. SCHICK

QuickLinks - Click here to rapidly navigate through this document Exhibit 10.21.2 ALLOS THERAPEUTICS, INC. SECOND AMENDMENT TO EMPLOYMENT AGREEMENT MICHAEL E. SCHICK This SECOND AMENDMENT TO EMPLOYMENT AGREEMENT (this "Second Amendment") is entered into effective as of September 7, 2011, by and between ALLOS THERAPEUTICS, INC. (the "Company") and MICHAEL E. SCHICK ("Executive") (collectively, the

Annual Report - 10-K

Use these links to rapidly review the document TABLE OF CONTENTS Index to Financial Statements Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

SIXTH AMENDMENT TO OFFICE LEASE AGREEMENT

Exhibit 10.5.4 SIXTH AMENDMENT TO OFFICE LEASE AGREEMENT THIS SIXTH AMENDMENT TO OFFICE LEASE AGREEMENT (this "Amendment"), dated as of December 7, 2011, (the "Effective Date") is entered into by and between CIRCLE POINT PROPERTIES, LLC, a Delaware limited liability company (the "Landlord") and ALLOS THERAPEUTICS, INC., a Delaware corporation (the "Tenant"). Recitals: A. Catellus Development Corpo

/s/ PAUL L. BERNS Paul L. Berns President and Chief Executive Officer (Principal Executive Officer)

QuickLinks - Click here to rapidly navigate through this document EXHIBIT 31.01 CERTIFICATION I, Paul L. Berns, certify that: 1. I have reviewed this annual report on Form 10-K of Allos Therapeutics, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstanc

/s/ DAVID C. CLARK David C. Clark Vice President, Finance and Treasurer (Principal Financial and Accounting Officer)

QuickLinks - Click here to rapidly navigate through this document EXHIBIT 31.02 CERTIFICATION I, David C. Clark, certify that: 1. I have reviewed this annual report on Form 10-K of Allos Therapeutics, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstan

-

*FOIA Confidential Treatment Request* Confidential Treatment Requested by Allos Therapeutics, Inc.

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2012 (March 13, 2012) ALLOS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-29815 54-1655029 (State or other jurisdiction of incorpora

- NT 10-K

OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB Number: 3235-0058 Expires: June 30, 2012 Estimated average burden hours per response . . . . . . 2.50 SEC FILE NUMBER 00029815 CUSIP NUMBER 019777101 (Check one): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: Dece

-

*FOIA Confidential Treatment Request* Confidential Treatment Requested by Allos Therapeutics, Inc.

Allos Therapeutics Reports Fourth Quarter and Full Year 2011 Financial Results - Conference Call Scheduled for Today at 4:30 p.m. ET -

Exhibit 99.1 Contact: Monique Greer 720-540-5268 [email protected] Allos Therapeutics Reports Fourth Quarter and Full Year 2011 Financial Results - Conference Call Scheduled for Today at 4:30 p.m. ET - WESTMINSTER, Colo., March 6, 2012 — Allos Therapeutics, Inc. (NASDAQ: ALTH) today reported financial results for the fourth quarter and full year ended December 31, 2011. Financial Highlights: · $15.

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2012 ALLOS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-29815 54-1655029 (State or other jurisdiction (Commission (IRS Employer of i

ALLOS THERAPEUTICS, INC. 2008 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE

Exhibit 10.2 ALLOS THERAPEUTICS, INC. 2008 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE Allos Therapeutics, Inc. (the “Company”), pursuant to Section 6(b) of the Company’s 2008 Equity Incentive Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award covering the number of restricted stock units (the “RSUs”) set forth below (the “Award”). This Award shall be eviden

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2012 (February 28, 2012) ALLOS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-29815 54-1655029 (State or other jurisdiction (Commissio

-

March 5, 2012 Jim B. Rosenberg Sasha Parikh Gus Rodriguez United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington D.C. 20549 Re: Allos Therapeutics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2010 Filed on March 3, 2011 Form 10-Q for the Quarterly Period Ended September 30, 2011 Filed on November 3, 2011 File No. 000-29815 Ladies an

2011 Bonus Award

Exhibit 10.1 Executive Compensation and Equity Awards At a meeting of the Compensation Committee of the Board of Directors of Allos Therapeutics, Inc. (the “Company”) held on February 28, 2012, the Compensation Committee (a) determined and approved 2011 cash bonus awards and 2012 base salaries and target bonus awards (expressed as a percentage of base salary) for the Company’s “named executive off

ALLOS THERAPEUTICS, INC. 2008 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE FOR NON-EMPLOYEE

Exhibit 10.1 ALLOS THERAPEUTICS, INC. 2008 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE FOR NON-EMPLOYEE DIRECTORS Allos Therapeutics, Inc. (the “Company”), pursuant to Section 6(b) of the Company’s 2008 Equity Incentive Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award covering the number of restricted stock units (the “RSUs”) set forth below (the “Award”).

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2012 (February 21, 2012) ALLOS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-29815 54-1655029 (State or other jurisdiction (Commi

-

February 22, 2012 Jim B. Rosenberg Sasha Parikh Gus Rodriguez United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington D.C. 20549 Re: Allos Therapeutics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2010 Filed on March 3, 2011 Form 10-Q for the Quarterly Period Ended September 30, 2011 Filed on November 3, 2011 File No. 000-29815 Ladie

ALTH / Allos Therapeutics Inc / WELLINGTON MANAGEMENT GROUP LLP - DISCLOSURE DOCUMENT Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Allos Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 019777101 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this

Allos Therapeutics Requests Re-Examination of CHMP Opinion on FOLOTYN® in PTCL at the European Medicines Agency

Exhibit 99.1 Contact: Monique Greer 720-540-5268 [email protected] Allos Therapeutics Requests Re-Examination of CHMP Opinion on FOLOTYN® in PTCL at the European Medicines Agency WESTMINSTER, Colo., Monday, January 30, 2012 — Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion iss

Financial Statements and Exhibits, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2012 (January 30, 2012) ALLOS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-29815 54-1655029 (State or other jurisdiction (Commiss

Allos Therapeutics Receives Negative Opinion from the CHMP on FOLOTYN — Plans to Submit Request for Re-examination of the CHMP Opinion —

EX-99.1 2 a12-30422ex99d1.htm EX-99.1 Exhibit 99.1 Contact: Monique Greer 720-540-5268 [email protected] Allos Therapeutics Receives Negative Opinion from the CHMP on FOLOTYN — Plans to Submit Request for Re-examination of the CHMP Opinion — WESTMINSTER, Colo., January 20, 2012 — Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced that the European Medicines Agency (EMA) Committee for Medicinal

Financial Statements and Exhibits, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 20, 2012 ALLOS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-29815 54-1655029 (State or other jurisdiction (Commission (IRS Employer o

-

*FOIA Confidential Treatment Request* Confidential Treatment Requested by Allos Therapeutics, Inc.

ALLOS THERAPEUTICS REPORTS 2011 FINANCIAL HIGHLIGHTS AND KEY BUSINESS PRIORITIES — Reports Fourth Quarter FOLOTYN® Net Product Sales of $15.4 Million, A 17% Increase Over Third Quarter 2011 —

Exhibit 99.1 Contact: Monique Greer 720-540-5268 [email protected] ALLOS THERAPEUTICS REPORTS 2011 FINANCIAL HIGHLIGHTS AND KEY BUSINESS PRIORITIES — Reports Fourth Quarter FOLOTYN® Net Product Sales of $15.4 Million, A 17% Increase Over Third Quarter 2011 — WESTMINSTER, Colo., January 10, 2012 — Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical company committed to the development and c

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2012 ALLOS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-29815 54-1655029 (State or other jurisdiction (Commission (IRS Employer o

-

Matthew P. Dubofsky VIA EDGAR CORRESPONDENCE FILING (720) 566-4244 [email protected] December 27, 2011 Mr. Jim B. Rosenberg Senior Assistant Chief Accountant Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Letter dated December 23, 2011 related to Allos Therapeutics, Inc.’s Form 10-K for the fiscal year ended December 31, 2010 filed